Skip to main content
. 2021 Apr 20;21:432. doi: 10.1186/s12885-021-08078-y

Fig. 4.

Fig. 4

Correlation between the clinical response to atezolizumab in the IMVigor 210 study according to RECIST v1.1 criteria and a the Tumor Mutational Burden (TMB) and b the TMM. CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive disease. ** P value < 0.01; *** P value < 0.001, Wilcoxon rank sum test, two-sided